PepEvolutionTriptorelin
Trelstar
A potent FDA-approved GnRH agonist for prostate cancer — strong oncology evidence, but a heavy drug repurposed off-label for a hormonal "restart."
Verdict — C · Emerging / Mixed
Strong, FDA-approved oncology evidence behind a genuinely potent drug — but the off-label "restart" use is under-evidenced and the pharmacology is unforgiving (flare effect, deep suppression, narrow margin for casual use). A C: real medicine, wrong-context use, and unverified gray-market sourcing.
Overview
Triptorelin is a long-acting GnRH agonist FDA-approved (Trelstar) for the palliative treatment of advanced prostate cancer, with a deep oncology evidence base. In the gray market it is used off-label as a single-dose hypothalamic-pituitary-gonadal "restart" after androgen cycles. That repurposing carries the same powerful pharmacology as the oncology use: an initial testosterone flare, profound downstream suppression, and broad contraindications. The approved evidence is strong but is not evidence for the off-label restart use.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.